LEARN ABOUT INHALED INSULIN FROM DR. EDELMAN AND DR. PETTUS
From insulin pumps to CGMs, they've personally tried every diabetes management tool available. As both doctors AND patients, they bring insights from decades of real-world experience with diabetes technologies and treatments, including their journey with Afrezza–Human inhaled insulin.
KEY FACTORS TO CONSIDER ABOUT INHALED INSULIN FROM AFREZZA:
Rapid on rapid off time course of action for better post-meal blood sugar, less delayed hypoglycemia.
Reduced hypoglycemia while exercising (fewer lows during exercise)
Effective at correcting high blood sugars
Convenient and easy to use in public (instead of needle pricks)
If you need multiple correction doses throughout the day, it’s super easy, convenient, and needle-free (we hate pricks!) You can help your doctor take better care of you by arming yourself with knowledge about Afrezza and making a reasonable case for why you should try it. It’s really up to you to take control of your diabetes.
📊 Remember Drs. Edelman and Pettus discussed the ‘INHALE 3’ study in the video? Below are some key points to learn!
More subjects utilizing inhaled insulin achieved glycemic targets:
- 30% of the inhaled insulin group reached <7% (HbA1c) at 17 weeks vs. 17% of the usual care group
- 21% of the inhaled insulin group vs. 0% of the usual care group met the A1c goal of <7% if the baseline was >7%
- 24% of the Afrezza group and 13% of the usual care group achieved TIR above 70% with no increased hypoglycemia in the inhaled insulin group
- More than 50% of subjects at the end of the study expressed an interest in continuing to use Afrezza
- Afrezza demonstrated significantly improved glucose values after a mixed meal tolerance test compared to those under usual care (red line), which only got better after the Afrezza dose was adjusted over time (yellow line)
